Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Up 138.1% in July

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 73,800 shares, a growth of 138.1% from the June 30th total of 31,000 shares. Based on an average trading volume of 262,500 shares, the short-interest ratio is currently 0.3 days. Approximately 0.8% of the shares of the stock are short sold.

Shuttle Pharmaceuticals Stock Up 5.5 %

Shares of NASDAQ:SHPH traded up $0.02 during trading on Friday, reaching $0.44. 154,103 shares of the company’s stock traded hands, compared to its average volume of 188,736. Shuttle Pharmaceuticals has a fifty-two week low of $0.35 and a fifty-two week high of $0.95. The firm has a market cap of $7.39 million, a PE ratio of -0.96 and a beta of -0.91. The company has a 50-day simple moving average of $0.43 and a 200-day simple moving average of $0.42.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.10) earnings per share for the quarter.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .